Condition

Abemaciclib

ClinicalTrials.gov condition label

Clinical trials6

Recruiting4

Common interventions7

Lead sponsors shown6

Clinical trials

6 shown

Evaluation of Adherence to Cell Cycle Inhibitors Used as Adjuvant Therapy in Patients With Localized Breast Cancer at High Risk of Recurrence.NCT07443774 · 2026-05-26

Observational Study of Gut Microbiota in Abemaciclib-Treated Patients With and Without DiarrheaNCT07264998 · 2025-12-21

Adjuvant Abemaciclib for Locoregional Recurrence of HR-positive, HER2-negative Breast Cancer (JCOG2313, AURA)NCT07190443 · 2025-02-07

Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 StudyNCT06805812 · 2023-05-01

Pharmacokinetic Model of Abemaciclib: Correlation With Severe Diarrhea as the Primary Toxicity Endpoint in Patients With Localized Hormone Receptor-positive Breast CancerNCT07490509 · 2026-09-01

NOT_YET_RECRUITING

Retrospective Observational Study of the Safety and Toxicity Management of Abemaciclib in Combination with Adjuvant Hormone Therapy in Patients with RH+ ,HER2-nonoveramplified Breast Cancer, Real-life Data (MONARCHE29)NCT06621459 · 2024-09-26

Common interventions

AbemaciclibDRUG1 Blood samples for PKBIOLOGICAL1 Endocrine Therapy (ET): letrozole, anastrozole, exemestane, tamoxifenDRUG1 Endocrine therapy + AbemaciclibDRUG1 PalbociclibDRUG1 QuestionnaireOTHER1 RibociclibDRUG1

Leading sponsors

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano1 Hubei Cancer Hospital1 Japanese Foundation for Cancer Research1 Poitiers University Hospital1 University Hospital, Brest1 University Hospital, Grenoble1

Trial status mix

RECRUITING4

NOT_YET_RECRUITING1

UNKNOWN1

Phase mix

PHASE31

PHASE41

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.